Advisor Group Holdings, Inc. Seelos Therapeutics, Inc. Transaction History

Advisor Group Holdings, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$0.16 - $1.64 $101,357 - $1.04 Million	633,483 Added 6082.99%	643,897 $115,000
Q1 2023 May 12, 2023	SELL	$0.59 - $1.04 $5,015 - $8,840	-8,500 Reduced 44.94%	10,414 $7,000
Q3 2022 Nov 14, 2022	SELL	$0.65 - $278.68 $162 - $69,670	-250 Reduced 1.3%	18,914 $20,000
Q2 2022 Aug 10, 2022	SELL	$0.51 - $0.93 $255 - $465	-500 Reduced 2.54%	19,164 $13,000
Q1 2022 May 04, 2022	SELL	$0.84 - $1.71 $5,166 - $10,518	-6,151 Reduced 23.83%	19,664 $16,000
Q3 2021 Nov 05, 2021	BUY	$1.69 - $2.89 $7,588 - $12,976	4,490 Added 21.06%	25,815 $62,000
Q2 2021 Aug 02, 2021	BUY	$2.64 - $6.32 $37,733 - $90,331	14,293 Added 203.26%	21,325 $56,000
Q1 2021 May 13, 2021	SELL	$1.35 - $4.99 $6,262 - $23,148	-4,639 Reduced 39.75%	7,032 $35,000
Q4 2020 Feb 10, 2021	SELL	$0.74 - $2.01 $24 - $66	-33 Reduced 0.28%	11,671 $18,000
Q3 2020 Nov 12, 2020	BUY	$0.6 - $1.25 $5,184 - $10,800	8,640 Added 281.98%	11,704 $11,000
Q2 2020 Aug 14, 2020	BUY	$0.42 - $1.51 $420 - $1,510	1,000 Added 48.45%	3,064 $3,000
Q1 2020 May 18, 2020	BUY	$0.47 - $1.56 $970 - $3,219	2,064 New	2,064 $1,000

40.5K

Ticker SEEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 106,691,000
Market Cap $312M
Description
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.